Pay in 4 interest-free payments of $5.28 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
T., Roberts, B
The STEP 1 trial showed semaglutide 2.4 mg led to 14.9% weight loss over 68 weeks, while SURMOUNT-1 showed tirzepatide achieved up to 20.9% weight reductionapproaching bariatric surgery outcomes.[6] The SELECT trial (17,604 patients) found semaglutide reduced cardiovascular death, non-fatal heart attack, and non-fatal stroke by 20% and all-cause mortality by 19%, suggesting direct cardioprotective effects beyond weight loss.[4] In STEP-HFpEF, semaglutide produced 13.3% weight loss in heart failure patients and improved symptoms and physical function
[15] [16] Tirzepatide (Mounjaro), a dual GIP/GLP-1 receptor agonist manufactured by Eli Lilly the same company developing retatrutide has also received MHRA approval
Dosing, support, and expectations are tailored to your unique physiology and goals
A.CoskunT.SammsR
